Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS)

Health Canada carried out a safety review after finding international cases of DRESS suspected of being linked with the use of Uloric (febuxostat). DRESS describes a group of rare, but serious and potentially life-threatening, side effects of a medication, with symptoms such as fever, severe skin rash with swollen face or peeling of the skin over large areas of the body, etc. These reactions usually happen two weeks to two months after starting a medication.

Data and Resources

Additional Info

Field	Value
Last Updated	April 17, 2026, 21:42 (UTC)
Created	April 17, 2026, 21:42 (UTC)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2017-05-18 00:00:00
open_canada_keywords	{"fr": ["Résumé de l'examen de l'innocuité", "ULORIC", "febuxosta", "évaluation", "risque possible", "réaction médicamenteuse/éruption cutanée avec éosinophilie et symptômes systémiques (DRESS)"], "en": ["Summary Safety Review", "ULORIC", "febuxosta", "assessing", "possible risk", "Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS)"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Résumé de l'examen de l'innocuité - ULORIC (fébuxostat) - Évaluation d'un risque possible de syndrome d'hypersensibilité médicamenteuse (syndrome DRESS)
update_frequency	as_needed